1 | 2 | 3 | |
---|---|---|---|
Unmet Need |
|
|
|
Status |
|
|
|
Clinical Phase & IP |
|
|
|
Molecule | 7 Methyl Xanthine |
Ketone Ester |
Algal DHA oil |
Investment in women’s and maternal health and care at birth will reduce pre-term birth rates and improve outcomes for women and newborn pre-term babies.
Investment in women’s and maternal health and care at birth will reduce pre-term birth rates and improve outcomes for women and newborn pre-term babies.
Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation), and this number is rising.
Preterm birth complications are the leading cause of death among children under 5 years of age, responsible for approximately 1 million deaths in 2015 (1).
Three-quarters of these deaths could be prevented with current, cost-effective interventions. Across 184 countries, the rate of preterm birth ranges from 5% to 18% of babies born.
The 10 countries with the greatest number of preterm births(2) | |
---|---|
India | 35,19,100 |
China | 11,72,300 |
Nigeria | 7,73,600 |
Pakistan | 7,48,100 |
Indonesia | 6,75,700 |
United States of America | 5,17,400 |
Bangladesh | 4,24,100 |
Philippines | 3,48,900 |
Democratic Republic of the Congo | 3,41,400 |
Brazil | 2,79,300 |
Progesterone Therapy, Corticosteroid Therapy, Tocolytics Therapy, Antibiotics Therapy, Heparin Prophylaxis therapy amongst others, through oral, parenteral, or vaginal routes.
Two recent trials investigating preterm birth did not find beneficial effect of progesterone. No effect on child development. Outcomes after first trimester progesterone are unclear.
Nine members of the FDA’s Bone, Reproductive and Urologic Drugs Advisory Committee have voted to recommend that the FDA pursue withdrawal of approval for hydroxyprogesterone caproate injection for the prevention of preterm birth in pregnant women, while 7 of the committee’s members voted to leave the product under accelerated approval and to require a new confirmatory trial.